CL
OCUL icon

CSS LLC’s Ocular Therapeutix OCUL Stock Holding History

CSS LLC’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,809
Closed -$72.5K – 847
2022
Q4 		$72.5K Sell
25,809
-61,261
-70% -$203K ﹤0.01% 717
2022
Q3 		$361K Buy
87,070
+52,500
+152% +$264K 0.02% 603
2022
Q2 		$139K Hold
34,570
– – 0.01% 856
2022
Q1 		$171K Buy
34,570
+22,500
+186% +$125K 0.01% 873
2021
Q4 		$84K Buy
12,070
+1,500
+14% +$11.6K ﹤0.01% 1042
2021
Q3 		$106K Buy
+10,570
New +$119K ﹤0.01% 969
2021
Q2 		– Sell
-14,814
Closed -$243K – 1146
2021
Q1 		$243K Sell
14,814
-13,186
-47% -$254K 0.01% 725
2020
Q4 		$580K Buy
28,000
+21,723
+346% +$323K 0.02% 428
2020
Q3 		$48K Sell
6,277
-2,159
-26% -$17.9K ﹤0.01% 715
2020
Q2 		$70K Buy
8,436
+7,256
+615% +$48.1K ﹤0.01% 571
2020
Q1 		$6K Buy
+1,180
New +$5.83K ﹤0.01% 584

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CSS LLC's OCUL Position: Q1 2023 in Review

CSS LLC sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 25,809 shares — an estimated $72.5K sold.

CSS LLC first reported a position in OCUL in Q1 2020 and held it in 11 quarters. The position peaked at $580K in Q4 2020. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

  • CSS LLC reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
  • CSS LLC sold 25,809 Ocular Therapeutix shares in Q1 2023, an estimated $72.5K.
  • CSS LLC first reported a position in Ocular Therapeutix in Q1 2020 and held it in 11 quarters.
  • CSS LLC's Ocular Therapeutix position peaked at $580K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.